SCHEMBL16208342

SCHEMBL16208342

N#Cc1ccc(NC(=O)CSc2nc3cc(Cl)ccc3s2)cc1Cl

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.56
KMT2A Q03164 8/20 0.56
ALDH1A1 P00352 7/20 0.56
MEN1 O00255 6/20 0.56
GAA P10253 1/20 0.56
AGPAT2 O15120 1/20 0.56
MAPT P10636 10/20 0.55
LMNA P02545 4/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
HSD17B10 Q99714 2/20 0.54
USP2 O75604 1/20 0.54
HTT P42858 1/20 0.54
POLB P06746 2/20 0.54
RAB9A P51151 2/20 0.50
NPSR1 Q6W5P4 2/20 0.50
RXFP1 Q9HBX9 1/20 0.50
ESR1 P03372 1/20 0.50
NPC1 O15118 1/20 0.49
HPGD P15428 1/20 0.49
TSHR P16473 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16208341 0.87 KMT2A (0.57) PTPN1KMT2AALDH1A1MEN1GAA
SCHEMBL17531742 0.81 KMT2A (0.56) PTPN1KMT2AALDH1A1MEN1GAA
SCHEMBL16208430 0.78 KMT2A (0.56) KMT2AALDH1A1MEN1MAPTLMNA
SCHEMBL16208340 0.77 MAPT (0.66) KMT2AALDH1A1MEN1MAPTLMNA
SCHEMBL30833314 0.77 MEN1 (0.82) KMT2AALDH1A1MEN1GAAMAPT
SCHEMBL29181052 0.77 MEN1 (0.82) KMT2AALDH1A1MEN1GAAMAPT
SCHEMBL11099223 0.74 ALDH1A1 (0.65) KMT2AALDH1A1MEN1GAAMAPT
SCHEMBL1269542 0.73 MAPT (0.66) KMT2AALDH1A1MEN1GAAMAPT
SCHEMBL11115997 0.73 KMT2A (0.66) KMT2AALDH1A1MEN1GAAMAPT
SCHEMBL28504268 0.72 MEN1 (0.63) KMT2AALDH1A1MEN1GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9643933-B2 Compounds useful as antibiotic tolerance inhibitors THE GENERAL HOSPITAL CORPORATION (US) 2017-05-09 US disclosed
US-9643933-B2 Compounds useful as antibiotic tolerance inhibitors THE GENERAL HOSPITAL CORPORATION (US) 2017-05-09 US disclosed
US-20160052890-A1 COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS THE GENERAL HOSPITAL CORPORATION (US) 2016-02-25 US disclosed
US-20160052890-A1 COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS THE GENERAL HOSPITAL CORPORATION (US) 2016-02-25 US disclosed
WO-2014176258-A1 COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS THE GENERAL HOSPITAL CORPORATION (US) 2014-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160052890-A1 COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS CFTR, SLC11A2, MRPS18A PTPN1 45/4885KMT2A 1369/4885ALDH1A1 2988/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.